<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156750</url>
  </required_header>
  <id_info>
    <org_study_id>17612</org_study_id>
    <secondary_id>J2P-MC-LXBA</secondary_id>
    <nct_id>NCT04156750</nct_id>
  </id_info>
  <brief_title>A Study of LY3556050 in Healthy Participants</brief_title>
  <official_title>Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study With LY3556050 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about the safety of LY3556050 after it is&#xD;
      given by mouth to healthy participants. Blood tests will be performed to check how much&#xD;
      LY3556050 gets into the bloodstream and how long the body takes to get rid of it. Each&#xD;
      enrolled participant will receive multiple doses of LY3556050 or placebo and will remain in&#xD;
      the study for up to 31 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2019</start_date>
  <completion_date type="Actual">August 3, 2020</completion_date>
  <primary_completion_date type="Actual">August 3, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part A - Parallel design. Part B - Open label design.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Part A - Double-blind. Part B - Open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through Final Follow-up (up to Week 9)]</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3556050</measure>
    <time_frame>Baseline through Day 17</time_frame>
    <description>PK: Cmax of LY3556050</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ)</measure>
    <time_frame>Baseline through Day 17</time_frame>
    <description>PK: AUCτ of LY3556050</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3556050 (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3556050 administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part A)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iohexol (Part B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Iohexol given intravenously (IV). (Part B is optional.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin (Part B)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metformin given orally. (Part B is optional.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3556050+ Iohexol (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iohexol given intravenously (IV) coadministered with oral doses of LY3556050. (Part B is optional.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3556050 + Metformin (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin given orally coadministered with oral doses of LY3556050. (Part B is optional.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3556050</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3556050 (Part A)</arm_group_label>
    <arm_group_label>LY3556050 + Metformin (Part B)</arm_group_label>
    <arm_group_label>LY3556050+ Iohexol (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Placebo (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Administered IV.</description>
    <arm_group_label>Iohexol (Part B)</arm_group_label>
    <arm_group_label>LY3556050+ Iohexol (Part B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3556050 + Metformin (Part B)</arm_group_label>
    <arm_group_label>Metformin (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy males or females of nonchild bearing potential, as determined by medical&#xD;
             history&#xD;
&#xD;
          -  Have safety laboratory results within normal references ranges&#xD;
&#xD;
          -  Weight at least 50 kilograms (kg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have known allergies to LY3556050, iodine, metformin and related compounds&#xD;
&#xD;
          -  Abnormal electrocardiogram (ECG) or blood pressure at screening&#xD;
&#xD;
          -  Significant history of current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, psychiatric or endocrine disorders&#xD;
&#xD;
          -  Show evidence of active renal disease with estimated glomerular filtration rate (GFR)&#xD;
             &lt;90 milliliters per minute per 1.73 meters squared&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 15, 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

